These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32006630)

  • 1. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.
    Kiesslich S; Vila-Chã Losa JP; Gélinas JF; Kamen AA
    J Biotechnol; 2020 Feb; 310():32-39. PubMed ID: 32006630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
    Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
    Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.
    Gélinas JF; Azizi H; Kiesslich S; Lanthier S; Perdersen J; Chahal PS; Ansorge S; Kobinger G; Gilbert R; Kamen AA
    Vaccine; 2019 Oct; 37(44):6624-6632. PubMed ID: 31548015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.
    Mangion M; Gélinas JF; Bakhshi Zadeh Gashti A; Azizi H; Kiesslich S; Nassoury N; Chahal PS; Kobinger G; Gilbert R; Garnier A; Gaillet B; Kamen A
    Vaccine; 2020 Nov; 38(50):7949-7955. PubMed ID: 33139138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of suspension adapted Vero cell culture process technology for production of viral vaccines.
    Shen CF; Guilbault C; Li X; Elahi SM; Ansorge S; Kamen A; Gilbert R
    Vaccine; 2019 Nov; 37(47):6996-7002. PubMed ID: 31288997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor.
    Berrie DM; Waters RC; Montoya C; Chatel A; Vela EM
    Vaccine; 2020 Apr; 38(20):3639-3645. PubMed ID: 32247568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.
    Carnino L; Vetter P; Peyraud N; Aebischer-Perone S; Chappuis F; Huttner A; Kaiser L; Eperon G
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34128975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
    Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
    Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.
    Kasereka MC; Ericson AD; Conroy AL; Tumba L; Mwesha OD; Hawkes MT
    Vaccine; 2020 Mar; 38(14):3003-3007. PubMed ID: 32093984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
    Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
    BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
    Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
    Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.
    Tsuda Y; Safronetz D; Brown K; LaCasse R; Marzi A; Ebihara H; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1090-7. PubMed ID: 21987746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
    Rourou S; Ben Zakkour M; Kallel H
    Vaccine; 2019 Nov; 37(47):6987-6995. PubMed ID: 31201054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
    Kiesslich S; Kamen AA
    Biotechnol Adv; 2020 Nov; 44():107608. PubMed ID: 32768520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study.
    Meakin S; Nsio J; Camacho A; Kitenge R; Coulborn RM; Gignoux E; Johnson J; Sterk E; Musenga EM; Mustafa SHB; ; Finger F; Ahuka-Mundeke S
    Lancet Infect Dis; 2024 Aug; ():. PubMed ID: 39178866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.